Is Enasidenib used long-term?

Enasidenib (Enasidenib) is a drug, also known as Idhifa, mainly used to treat a specific type of acute myeloid leukemia (AML) in which there is a mutation in the IDH2 gene. However, whether long-term use of ensidipine is necessary depends on the patient's specific situation and the advice of the doctor.

In clinical trials of ensidipine, half of the 214 patients evaluated for safety took ensidipine for more than 4.3 months, while half took it for less than that (ranging from 0.3 to 23.6 months). Among the patients evaluated for efficacy, and those in whom ensidipine worked (46 out of 199), the time it took to observe a response varied: half of the patients took ensidipine for 1.9 months First response occurred after 0.5 to 7.5 months (0.5 to 7.5 months), while half of the patients took longer. Half of the patients had best response after 3.7 months (0.6 to 11.2 months) of ensidipine, while half of the patients took longer.

Ensiidi plain investigational medicine is not currently on the market in the country, nor is it covered by medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic encidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*60 tablets produced by a Bangladesh pharmaceutical factory may be around 4,000 yuan per box (the price may fluctuate due to exchange rates). Its drug ingredients are basically the same as those of the original encidipine generic drug.